A little over a year ago Dr. Mario Carrillo, Director of Medical and Scientific Relations for the Alzheimer’s Association, traveled to Portland to give our staff, board members, and donors an update on where we stand in Alzheimer’s research. I blogged about it at the time because she’s an incredible speaker, completely adept at translating complicated scientific principals into concepts that are easy to understand. One of the drugs on her radar at the time was Dimebon, a Russian anti-histamine that seemed to improve the symptoms of Alzheimer’s. The drug was fast tracked through clinical trials here in the U.S. and news over the last week is buzzing. Pfizer is preparing to release new studies on the Dimebon’s performance in early March and a number of financial institutions and media sites are speculating on the potential. Click here to read yesterday’s article on Bloomberg.com. The jury’s still out on how the drug will hold up in larger and more rigorous trails here in the United States, but needless to say I’ll be eagerly awaiting the results–stay tuned!
This entry was posted on Wednesday, February 3rd, 2010 at 8:18 am and is filed under Alzheimer's Info, Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
